ESX1 Inhibitors
Chemical inhibitors of ESX1 can achieve functional inhibition through various molecular pathways. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit kinases that may phosphorylate ESX1 or its co-regulators, thereby preventing ESX1 from fulfilling its role in transcription regulation. Similarly, Bisindolylmaleimide I, which specifically inhibits protein kinase C (PKC), can reduce the phosphorylation of proteins that regulate ESX1's activity. ESX1's function can also be inhibited by H-89, a protein kinase A (PKA) inhibitor, which can prevent PKA-dependent phosphorylation events that might be crucial for ESX1's regulatory functions. LY294002, as a PI3K inhibitor, downregulates AKT signaling, which in turn can reduce the activity of transcription factors and co-regulators involved with ESX1, leading to a decrease in ESX1 activity.
Additionally, PD98059 and U0126, both inhibitors of MEK in the MAPK pathway, can prevent the activation of ERK. The inhibition of this pathway can suppress the activity of transcription factors that are involved with ESX1, resulting in its functional inhibition. Rapamycin and AZD8055, inhibitors of mTOR, can disrupt the cellular conditions favorable for ESX1 activity, such as protein synthesis and other growth-related processes, thereby functionally inhibiting ESX1. Furthermore, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, can impede the regulatory impact of these kinases on transcription factors that control ESX1 activity. Lastly, Dasatinib and PP2, both Src family kinase inhibitors, can decrease the phosphorylation of substrates within ESX1's regulatory network, thus impeding ESX1 function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can inhibit a broad spectrum of kinases. Given that ESX1 is a homeobox protein involved in transcription regulation, staurosporine can inhibit kinases that might phosphorylate ESX1 or its co-regulators, thus inhibiting ESX1's function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). PKC may phosphorylate ESX1 or influence its regulatory pathways, so inhibition of PKC can lead to reduced ESX1 activity by preventing such phosphorylation events. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a protein kinase A (PKA) inhibitor. If ESX1 activity is modulated through PKA-dependent phosphorylation or regulatory pathways, H-89 can inhibit ESX1 activity by inhibiting PKA. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, this compound can downregulate AKT signaling. As AKT can regulate a variety of proteins including transcription factors, inhibition of this pathway can result in functional inhibition of ESX1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Inhibition of this pathway can result in reduced activity of transcription factors and co-regulators of ESX1 leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can influence transcriptional events and protein synthesis. By inhibiting mTOR, rapamycin can reduce the cellular conditions that favor ESX1 activity, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. The p38 MAPK pathway is involved in the regulation of transcription factors and protein synthesis. Inhibition by SB203580 can reduce ESX1 activity by affecting these transcriptional regulators. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. JNK influences transcription factor activity, and inhibition of JNK can disrupt transcriptional regulation involving ESX1, leading to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. While not directly linked to ESX1, Src kinases can phosphorylate a range of substrates that affect transcription factor activity and could be involved in ESX1's regulatory network, leading to its inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is another Src family kinase inhibitor. Similar to dasatinib, by inhibiting Src kinases, PP2 can decrease the phosphorylation of proteins that may interact with or regulate ESX1, thus functionally inhibiting ESX1. | ||||||